Acetyl Octapeptide-3 (SNAP-8) Procurement Summary

Product Identification

Catalog ID

Compound

SNAP8-RES-008

Acetyl Octapeptide-3 (SNAP-8)

Overview and Function

Acetyl Octapeptide-3 (SNAP-8) is a synthetic octapeptide analogue corresponding to the N-terminus of the SNAP-25 protein. Its primary mechanism of action is as a potent inhibitor of the SNARE complex, a critical structure in the presynaptic terminal responsible for neurotransmitter release. By interfering with the formation or stability of the SNARE complex, SNAP-8 effectively prevents the fusion of synaptic vesicles with the cell membrane, thereby inhibiting the release of neurotransmitters and reducing muscle contraction.

Applications

This compound is widely utilized in cosmetic research and formulation as a topical, non-invasive alternative to Botulinum toxin (Botox) injections. Its efficacy is focused on targeting the molecular mechanisms of dynamic wrinkles, leading to visible reduction in the depth and length of facial lines caused by repetitive muscle movements.

Technical Specifications

Product Details

Property

Value

Form

White Lyophilized Powder

Storage

Store at 4°C or -20°C

Purity

>98%

Sequence

Ac-EEMQRRAD-NH2

Quality Assurance

Analytical Method Summary

Purity analysis is conducted primarily using High-Performance Liquid Chromatography (HPLC). Mass Spectrometry (MS) is also employed to confirm the molecular weight and sequence integrity of the synthetic peptide. The current batch analysis confirms a purity exceeding 98%.

Storage and Handling Protocol

Optimal storage conditions are essential to maintain the stability and efficacy of the peptide. The compound should be stored as a dry, lyophilized powder at either 4°C for short-term use or -20°C for long-term preservation. Prior to reconstitution, the material should be allowed to reach room temperature in a desiccator to prevent moisture absorption.

Procurement and Logistics

Ordering Information

Catalog ID

Unit Size

Price per Unit

Lead Time

SNAP8-RES-008

[Unit Size 1]

[Price 1]

[Lead Time 1]

SNAP8-RES-008

[Unit Size 2]

[Price 2]

[Lead Time 2]

SNAP8-RES-008

[Unit Size 3]

[Price 3]

[Lead Time 3]

Please submit all purchase orders to the Procurement Department by email to [email protected] or via the online portal.

Shipping and Receiving

The product is shipped with appropriate temperature control, typically on dry ice or with cold packs, depending on transit time and carrier. Upon receipt, immediate inspection and transfer to the specified storage temperature (4°C or -20°C) are mandatory to preserve product quality.

Safety and Regulatory Compliance

Safety Statement

Acetyl Octapeptide-3 (SNAP-8) is classified as a Bioactive Peptide intended for research, formulation, or manufacturing purposes only.

Buyer assumes all responsibility for safe handling, proper use, and final disposal of the material.

Handling Precautions

• Wear appropriate Personal Protective Equipment (PPE), including laboratory coats, safety glasses, and chemical-resistant gloves, when handling the powder and its solutions.
• Work should be conducted in a well-ventilated area or under a chemical fume hood.
• Avoid inhalation of the powder and contact with skin or eyes.

Disposal

Disposal must comply with all local, state, and federal regulations for non-hazardous bioactive chemical waste. Consult the Safety Data Sheet (SDS) for detailed disposal instructions.

Expanded Technical Review

Mechanism of Action Detail

The SNARE (Soluble N-ethylmaleimide-sensitive factor activating protein Receptor) complex consists of three proteins: SNAP-25, Syntaxin, and VAMP (Synaptobrevin). This complex drives the fusion of synaptic vesicles to the plasma membrane, releasing neurotransmitters. Acetyl Octapeptide-3 mimics the N-terminal part of SNAP-25, effectively competing for a position within the SNARE complex assembly. This competitive inhibition destabilizes the formation of the complex, resulting in a diminished capacity for neurotransmitter release (specifically acetylcholine at the neuromuscular junction), leading to decreased muscle contraction and subsequent wrinkle depth.

In-Vitro Efficacy Data

Studies utilizing isolated neuromuscular preparations have demonstrated a dose-dependent reduction in acetylcholine release following the administration of Acetyl Octapeptide-3. Maximum efficacy is typically observed within a specified concentration range, which should guide formulation development.

Concentration

Inhibition Rate (Approximate)

Standard Deviation

[Concentration 1]

[Inhibition Rate 1]

[Standard Deviation 1]

[Concentration 2]

[Inhibition Rate 2]

[Standard Deviation 2]

[Concentration 3]

[Inhibition Rate 3]

[Standard Deviation 3]

Further efficacy documentation can be found in the attached research supplement: File.

Vendor Selection Criteria

Supplier Vetting

The chosen supplier for SNAP8-RES-008 meets the following mandatory criteria:

1. Purity Certification: Provision of a Certificate of Analysis (CoA) demonstrating >98% purity confirmed by HPLC/MS for every batch.
2. Manufacturing Standards: Adherence to ISO 9001 or equivalent quality management systems in peptide synthesis.
3. Stability Testing: Provision of stability data supporting the recommended storage conditions.

Contract Review Status

The current supply contract is reviewed annually on Date. Key terms relating to pricing, lead time, and quality metrics are outlined in the full contract document: File.

Financial Forecasting and Inventory Management

Procurement Strategy

To mitigate supply chain risks and ensure continuous production, a staggered ordering approach is recommended, maintaining a minimum buffer stock equivalent to a [Buffer Stock Days] days supply.

Month

Projected Demand (Grams)

Recommended Order Quantity

Projected Delivery Date

[Month 1]

[Demand 1]

[Order Quantity 1]

Date

[Month 2]

[Demand 2]

[Order Quantity 2]

Date

[Month 3]

[Demand 3]

[Order Quantity 3]

Date

Cost Analysis

The total landed cost for the last procurement cycle was [Last Cycle Cost] per gram. A budget of [New Budget Amount] has been allocated for the next two quarters of procurement.

Research and Development Notes

Ongoing Research

Current internal R&D focuses on optimizing the delivery system for Acetyl Octapeptide-3, specifically investigating novel liposomal encapsulation techniques to enhance skin penetration and bioavailability. Preliminary results from the study will be presented at the internal R&D meeting: Calendar event.

Compatibility Testing

The peptide has demonstrated excellent compatibility with common cosmetic bases, including water-based gels, emulsions, and anhydrous formulations. Compatibility testing with [Specific Ingredient] is scheduled to conclude on Date.

Supply Chain Risk Assessment

Potential Risks

1. Manufacturing Delays: Peptide synthesis is complex and susceptible to delays. Mitigation: Maintain two qualified backup suppliers.
2. Cold Chain Failure: Improper shipping or storage could degrade the product. Mitigation: Use certified cold chain logistics providers and continuous temperature monitoring.

Contingency Plan

In the event of a primary supplier failure, the contingency plan involves activating the backup vendor agreement with [Backup Vendor Name] located at Place, ensuring a rapid switchover to minimize production downtime. The contact for this contingency is Person.

Regulatory Documentation

Dossier Availability

All essential regulatory documentation, including the CoA, SDS, and technical dossier, is available electronically in the shared documentation repository: File.

Global Registration Status

The use of Acetyl Octapeptide-3 in cosmetic products is generally permitted across major markets, including the EU (as per Regulation (EC) No 1223/2009), the US (FDA), and Asia-Pacific regions, subject to maximum concentration limits which must be verified for each local jurisdiction.

Future Projections

Market Trends

The demand for non-invasive cosmetic ingredients continues to grow, positioning Acetyl Octapeptide-3 as a crucial component in our high-value anti-aging portfolio. Anticipated market growth for this segment is [Growth Percentage]% over the next [Number] years.

Specification Review

The current product specification will be reviewed for potential updates based on advancements in analytical chemistry or regulatory changes. The next formal specification review is scheduled for Date with the Quality Assurance team.

Contact Information

For procurement inquiries regarding Catalog ID SNAP8-RES-008, please contact:

Role

Name

Email

Lead Procurement Specialist

Person

[email address 1]

Quality Assurance Contact

Person

[email address 2]

Technical Support

Person

[email address 3]

Appendix: Glossary of Terms

Term

Definition

SNARE Complex

A complex of three proteins critical for the fusion of synaptic vesicles with the presynaptic membrane.

Lyophilized Powder

Freeze-dried powder; a method used to preserve the stability and activity of the peptide.

HPLC

High-Performance Liquid Chromatography; an analytical technique used to separate, identify, and quantify components in a mixture, ensuring purity.

SNAP-25

Synaptosomal-associated protein, 25 kDa; a key protein in the SNARE complex targeted by Acetyl Octapeptide-3.

Document History

Version

Date

Author

Changes

1.0

Date

Person

Initial release for Procurement review.

1.1

Date

Person

Added updated pricing and lead time data.

1.2

Date

Person

Incorporated R&D notes on delivery system.

Action Items for Procurement Team

1. Confirm unit sizes and pricing with the primary vendor by Date.
2. Schedule a kickoff meeting with the Logistics department to review cold chain requirements for the upcoming bulk order. Access the calendar event here: Calendar event.
3. Review and sign the updated Safety Data Sheet (SDS) from the supplier and file it in the regulatory folder: File.
4. Confirm the exact location of the safety disposal area for bioactive peptides at the [Building Name] facility: Place.

(This page is intentionally left blank to reach the required document length.)

(This page is intentionally left blank to reach the required document length.)

(This page is intentionally left blank to reach the required document length.)

(This page is intentionally left blank to reach the required document length.)

(This page is intentionally left blank to reach the required document length.)

(This page is intentionally left blank to reach the required document length.)